Methylene Blue Clinical Trials Database
Structured database of methylene blue clinical trials registered on ClinicalTrials.gov. Browse by condition, phase, and status. Links to published results where available. For the underlying science behind these trials, see our clinical evidence overview.
Filter by Condition
All Registered Trials
| NCT ID | Condition | Phase | Status | Year | Outcome |
|---|---|---|---|---|---|
| NCT01626391[PMC] | Cognitive Function | Phase II | Completed | 2016 | Improved fMRI BOLD signal during attention tasks (p<0.05) |
| NCT01689246 | Alzheimer's Disease | Phase III | Completed | 2016 | Primary endpoints not met; secondary signals in monotherapy |
| NCT01689233 | Alzheimer's Disease | Phase III | Completed | 2016 | Primary endpoints not met |
| NCT00515333 | Encephalopathy | Phase II | Completed | 2010 | Prevention of ifosfamide neurotoxicity |
| NCT01365390 | Vasoplegic Syndrome | Phase III | Completed | 2015 | Reduced vasopressor requirements |
| NCT00473616 | Malaria | Phase II | Completed | 2009 | Parasite clearance rates |
| NCT02380573 | Septic Shock | Phase II | Completed | 2018 | Hemodynamic stability outcomes |
| NCT03446001 | Depression | Phase II | Completed | 2020 | Hamilton Depression Rating Scale changes |
| NCT02594930 | Malaria | Phase III | Completed | 2017 | Fever clearance and parasite reduction |
| NCT04370288 | Alzheimer's Disease | Phase III | Completed | 2022 | Long-term safety and efficacy monitoring |
| NCT02819193[PMC] | Anxiety / PTSD | Phase I | Completed | 2018 | Fear extinction retention |
| NCT01253122 | Stroke | Phase II | Terminated | 2014 | Study terminated early |
Research Landscape by Condition
Cognitive Enhancement
The Rodriguez et al. (2016) study (NCT01626391) remains the highest-quality evidence for cognitive effects, using fMRI to demonstrate improved attention and memory retrieval.
View Brain Health Research →Alzheimer's Disease
Multiple Phase III trials of LMTM (TauRx) did not meet primary endpoints. Secondary analyses showed mixed signals. This is an honest acknowledgment of current trial status.
View Alzheimer's Research →Critical Care (Vasoplegic / Sepsis)
IV methylene blue has established clinical use for vasoplegic syndrome following cardiac surgery and septic shock. These represent the most successful clinical applications, with reduced vasopressor requirements documented.
Malaria
Multiple trials in endemic regions have studied MB as combination therapy. Results show antimalarial activity, though this represents a different use case than supplement-context research.
Understanding Clinical Trial Data
Database Methodology
This database includes trials registered on ClinicalTrials.gov with methylene blue as an intervention. Selection prioritizes trials with published results or completed status. IV administration trials (critical care) are included for completeness but represent different use cases than oral supplementation. For a transparent discussion of what this evidence supports and where gaps remain, see our balanced analysis of MB evidence. Last updated: March 2026.
Free: The Biohacker's 90-Day MB Protocol
Science-backed dosing schedule + stacking guide
- 3-phase titration protocol (weeks 1-12)
- Weight-based dosing tables
- Synergistic stacking protocols
- Biomarker tracking checklist
No spam. Unsubscribe anytime.